Shares of Krsnaa Diagnostics surged by 4% following the company's announcement of acquiring a 23.53% stake in Apulki Healthcare, a start-up specialising in oncology and cardiology. The acquisition aims to give Krsnaa exclusive rights to offer diagnostic services across Apulki's healthcare operations.
Investors are keen to buy shares online of Krsnaa Diagnostics as the move strengthens its strategic position in the diagnostic services sector.
Apulki Healthcare and Krsnaa's acquisition details
Apulki Healthcare, incorporated in 2022, focuses on establishing hospitals that primarily operate in oncology and cardiology, working under public-private partnership models. Krsnaa's acquisition of a 23.53% stake in the company is part of a broader strategy to expand its diagnostics services. The deal is expected to be finalised within three months, further enhancing Krsnaa's reach across critical healthcare areas.
This acquisition has contributed to a rise in Krsnaa's stock, now trading at ₹854.40 on the NSE as of September 26. Investors looking to buy shares online of Krsnaa Diagnostics have been quick to respond, given the company's strategic focus on expanding its market share in under-served regions.
Krsnaa's growing presence and PPP model
Krsnaa Diagnostics operates under a unique public-private partnership (PPP) model, which has allowed the company to expand rapidly into Tier II and Tier III markets. The company's competitive pricing model and established presence in these regions make it an attractive prospect for those looking to buy shares online. Over the past year, Krsnaa has opened 15 new CT/MRI centres, 21 pathology labs, 805 pathology collection centres, and 63 tele-reporting centres.
Recent tenders and upcoming projects
Krsnaa Diagnostics recently secured two major radiology tenders in Maharashtra and Madhya Pradesh, which will involve the installation of 23 MRI and 17 CT scan machines. Additionally, Krsnaa is in the process of setting up 57 radiology centres and has been awarded a tele-reporting contract for radiology services at the Bhabha Atomic Research Centre (BARC) hospital in Mumbai. The expected growth in radiology services for FY25 has been a significant factor driving investor interest in Krsnaa shares.
The combination of new tenders and the strategic acquisition of Apulki Healthcare positions Krsnaa for continued growth, further increasing interest from those looking to buy shares online of the company. The company's efforts in expanding its diagnostic services, particularly in radiology, indicate a bright outlook for the future.
Strong financial growth and future outlook
Krsnaa Diagnostics has experienced strong financial performance over the past year, with significant growth in revenue and operations. The company's ability to secure key contracts and expand its service network has resulted in a positive outlook for the coming financial years. The acquisition of Apulki Healthcare is expected to contribute to Krsnaa's revenue growth as it broadens its diagnostic capabilities in critical areas like oncology and cardiology.
For those looking to buy shares online, Krsnaa's steady growth and expansion through strategic acquisitions present an opportunity to invest in a company with a strong foothold in the healthcare sector. The company's public-private partnership model and recent tender wins further support its long-term growth prospects.
Final words
Krsnaa Diagnostics' acquisition of a 23.53% stake in Apulki Healthcare marks a significant step in its expansion strategy, strengthening its position in the diagnostic services sector. This acquisition, combined with the company's recent tender wins and growing presence in under-served markets, has driven investor interest, as reflected by the 4% jump in share price.
For those considering investment opportunities, Krsnaa Diagnostics presents a promising option for growth in the healthcare sector. The chance to buy shares online of a company with a strong track record, expansion plans, and a focus on accessible healthcare makes it an appealing choice for investors.
For android only